Skip to content
Nurix
Nurix
  • Inside The Science
    • DEL-AI Discovery Engine
    • Targeted Protein Degradation
    • Resource Library
  • Advancing Our Pipeline
    • Pipeline
    • Clinical Trials
  • Learn About Us
    • Our Story
    • Leadership
    • Partnering
    • Contact Us
  • Work at Nurix
    • Our Culture
    • Explore Jobs
For Patients
For Patients
For Investors
For Investors
Nurix
Nurix
  • Inside The Science
    • DEL-AI Discovery Engine
    • Targeted Protein Degradation
    • Resource Library
  • Advancing Our Pipeline
    • Pipeline
    • Clinical Trials
  • Learn About Us
    • Our Story
    • Leadership
    • Partnering
    • Contact Us
  • Work at Nurix
    • Our Culture
    • Explore Jobs

Discovery and Optimization of CBL-B Inhibitors 

By AldenMC Production / October 18, 2022
Post navigation
Previous

NX-1607, an inhibitor of the CBL-B E3 ubiquitin ligase, promotes favorable local and systemic changes in infiltrating immune cells in multiple mouse tumor models 

Next

Combining TIL with Small Molecule Inhibitors to Enhance T-Cell Expansion & Phenotypes

Nurix

WHERE SCIENCE EXPANDS POSSIBILITIES

Inside The Science

  • DEL-AI Discovery Engine
  • Targeted Protein Degradation
  • Resource Library

Advancing Our Pipeline

  • Pipeline
  • Clinical Trials

Learn About Us

  • Our Story
  • Leadership
  • Partnering
  • Contact Us

Work at Nurix

  • Our Culture
  • Explore Jobs

For Investors

  • News & Events
  • Financial Information
  • Stock Information
  • Corporate Governance
  • FAQs
  • Investor Contact

For Patients

  • Resources

©2025 Nurix Therapeutics, Inc.

Privacy Policy

Terms of Use

Cookie Policy

Privacy Policy

Terms of Use

Cookie Policy

You are now leaving the nurixtx.com website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Cancel
Continue